Influenza and other respiratory viruses · 2023
Type I interferon autoantibodies in hospitalized patients with Middle East respiratory syndrome and association with outcomes and treatment effect of interferon beta-1b in MIRACLE clinical trial.
Рандомизированное исследованиеСтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Alotaibi Faizah, Alharbi Naif Khalaf, Rosen Lindsey B, Asiri Ayed Y, Assiri Abdullah M, Balkhy Hanan H, Al Jeraisy Majed, Mandourah Yasser, AlJohani Sameera, Al Harbi Shmeylan, Jokhdar Hani A Aziz, Deeb Ahmad M, Memish Ziad A, Jose Jesna, Ghazal Sameeh, Al Faraj Sarah, Al Mekhlafi Ghaleb A, Sherbeeni Nisreen Murad, Elzein Fatehi Elnour, AlMutairi Badriah M, Al-Dawood Abdulaziz, Abdullah Mashan L, Barhoumi Tlili, Alenazi Mohammed W, Almasood Abdulrahman, Holland Steven M, Arabi Yaseen M, Saudi Critical Care Trials Group
Аннотация
BACKGROUND: Type I interferons (IFNs) are essential antiviral cytokines induced upon respiratory exposure to coronaviruses. Defects in type I IFN signaling can result in severe disease upon exposure to respiratory viral infection and are associated with worse clinical outcomes. Neutralizing autoantibodies (auto-Abs) to type I IFNs were reported as a risk factor for life-threatening COVID-19, but their presence has not been evaluated in patients with severe Middle East respiratory syndrome (MERS).
METHODS: We evaluated the prevalence of type I IFN auto-Abs in a cohort of hospitalized patients with MERS who were enrolled in a placebo-controlled clinical trial for treatment with IFN-β1b and lopinavir-ritonavir (MIRACLE trial). Samples were tested for type I IFN auto-Abs using a multiplex particle-based assay.
RESULTS: Among the 62 enrolled patients, 15 (24.2%) were positive for immunoglobulin G auto-Abs for at least one subtype of type I IFNs. Auto-Abs positive patients were not different from auto-Abs negative patients in age, sex, or comorbidities. However, the majority (93.3%) of patients who were auto-Abs positive were critically ill and admitted to the ICU at the time of enrollment compared to 66% in the auto-Abs negative patients. The effect of treatment with IFN-β1b and lopinavir-ritonavir did not significantly differ between the two groups.
CONCLUSION: This study demonstrates the presence of type I IFN auto-Abs in hospitalized patients with MERS.
METHODS: We evaluated the prevalence of type I IFN auto-Abs in a cohort of hospitalized patients with MERS who were enrolled in a placebo-controlled clinical trial for treatment with IFN-β1b and lopinavir-ritonavir (MIRACLE trial). Samples were tested for type I IFN auto-Abs using a multiplex particle-based assay.
RESULTS: Among the 62 enrolled patients, 15 (24.2%) were positive for immunoglobulin G auto-Abs for at least one subtype of type I IFNs. Auto-Abs positive patients were not different from auto-Abs negative patients in age, sex, or comorbidities. However, the majority (93.3%) of patients who were auto-Abs positive were critically ill and admitted to the ICU at the time of enrollment compared to 66% in the auto-Abs negative patients. The effect of treatment with IFN-β1b and lopinavir-ritonavir did not significantly differ between the two groups.
CONCLUSION: This study demonstrates the presence of type I IFN auto-Abs in hospitalized patients with MERS.